Intl. App. No.: PCT/EP 202278

Docket No. B45139

33. (Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection or cancer or allergy, comprising the mucosal administration of a safe and effective amount of a vaccine composition according to [any of claims 22 to 24] claim 22.

- 34. (Amended) A method of treating a mammal suffering from or susceptible to a pathogenic infection or cancer or allergy, comprising the intranasal administration of a safe and effective amount of a vaccine composition according to [any of claims 22 to 24] <u>claim</u> 22.
- 35. (Amended) A process for making a vaccine composition according to [any one of claims 22 to 24] <u>claim 22</u>, comprising admixing (a) and adjuvant composition as claimed in any of claims 1 to 21, (b) a pharmaceutically acceptable excipient, and (c) an antigen or antigenic composition.

REMARKS

The above-identified application is being entered into the National Phase from PCT application no. PCT/EP99/02278.

Applicants have cancelled claims 25-29, 31 and 36, and amended claims 3, 4, 6-8, 13, 14, 16, 19, 21, 22, 24, 32-35, to put the claims in conformity with U.S. practice.

No new matter has been introduced.

Respectfully submitted,

Zoltan Kerekes

Attorney for Applicants Registration No. 38,938

SMITHKLINE BEECHAM CORPORATION Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5024 Facsimile (610) 270-5090

N:\zk\apps\b45139\Preamd.doc